---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-221595"
form_type: "8-K"
ticker: "EQ"
cik: "0001746466"
company_name: "Equillium, Inc."
filed_at: "2026-05-13T20:05:19+00:00"
generated_at: "2026-05-13T22:12:24.357031+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Equillium Q1 net loss narrows to $5.3M; EQ504 Phase 1 on track for mid-2026

## Summary
- Q1 net loss of $5.3M ($0.06/sh) vs. $8.7M ($0.24/sh) in Q1 2025; R&D spending down to $3.0M.
- Cash and equivalents $61.3M as of March 31, 2026; funded into 2029; includes $35M March private placement.
- Phase 1 proof-of-mechanism study of EQ504 (AhR modulator) on track for mid-2026, data ~6 months later.
- Appointed Snehal Naik, Ph.D., as Chief Development Officer; she brings >15 years immunology experience.
- Evaluating further advancement of EQ302 (IL-15/IL-21 inhibitor) for GI indications.

## SEC filing metadata
- accession: 0001193125-26-221595
- form_type: 8-K
- ticker: EQ
- cik: 0001746466
- company_name: Equillium, Inc.
- filed_at: 2026-05-13T20:05:19+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1746466/000119312526221595/0001193125-26-221595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1746466/000119312526221595/eq-20260513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-221595
- JSON: https://secwatch.observer/filing/0001193125-26-221595.json
- Plain text: https://secwatch.observer/filing/0001193125-26-221595.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.